Chemotherapy dose intensity

Chemotherapy dose intensity has been studied in 1 paper since 2023: 1 observational study in people. The newest paper, Apr 28, 2023: “Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma”.

Exposure

1 paper studies it2 findingsUpdated

See all 1 papers on chemotherapy dose intensity

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Initial dose intensity (IDI) and relative dose intensity (RDI) had a significant impact on OS in fit patients.”
Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphomaAnnals of hematology2023doi:10.1007/s00277-023-05233-2

1 of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • 1 finding against
  • Humans1

What did studies of chemotherapy dose intensity find?

1

Studies of chemotherapy dose intensity measured one outcome, overall survival.

Overall survival

no changein humans1upin humans1

1 study
  1. Chemotherapy dose intensity was not clearly linked with overall survival in non-fit (unfit and frail) elderly patients with DLBCL.

    Humansin non-fit (unfit and frail) elderly patients with DLBCL

  2. Chemotherapy dose intensity is linked with better overall survival in fit elderly patients with DLBCL.

    Humansin fit elderly patients with DLBCL

Latest